This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Adverum Biotechnologies Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Der Gewinn von Adverum Biotechnologies wird voraussichtlich um 2.1% pro Jahr zurückgehen, während der Jahresumsatz um 87.4% pro Jahr wachsen soll. Der Gewinn je Aktie wird voraussichtlich um 21% pro Jahr steigen.

Wichtige Informationen

-2.1%

Wachstumsrate der Gewinne

20.97%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.2%
Wachstumsrate der Einnahmen	87.4%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	17 Nov 2025

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Seeking Alpha • Nov 18

Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients

Summary Adverum Biotechnologies, Inc. achieved positive results from both the LUNA and OPTIC studies, using Ixo-vec for the treatment of patients with wet age-related macular degeneration. The phase 3 ARTEMIS study, using Ixo-vec in combination with prophylactic regimens for the treatment of patients with wet age-related macular degeneration, expected to begin 1st half of 2025. The global age-related macular degeneration market is expected to reach $19.53 billion by 2032; About 10% of all AMD patients have wet age-related macular degeneration. The company had $153 million in cash as of September 30th of 2024; enough cash to fund its operations into the 2nd half of 2025. Read the full article on Seeking Alpha

Analyseartikel • Feb 24

We're Keeping An Eye On Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Analyseartikel • Sep 07

We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Seeking Alpha • Aug 11

Adverum Biotechnologies GAAP EPS of -$0.44 misses by $0.10

Adverum Biotechnologies press release (NASDAQ:ADVM): Q2 GAAP EPS of -$0.44 misses by $0.10. Cash, cash equivalents and short-term investments were $235.8 million as of June 30, 2022, compared to $305.2 million as of December 31, 2021. Adverum expects the June 30, 2022 cash position to fund operations into 2025. Shares -0.66% AH.

Seeking Alpha • Jul 07

Adverum gains 13% to reach three-month high after Truist upgrade

The shares of Adverum Biotechnologies (NASDAQ:ADVM) added ~13% to reach the highest level since March after Truist upgraded the clinical-stage gene therapy company to Buy from Hold noting the prospects for its wet AMD therapy ixo-vec. Wet age-related macular degeneration or wet AMD is the leading cause of blindness in people over the age of 65. The analysts led by Joon Lee cite clarity in the future development of ixo-vec, formerly known as ADVM-022 in wet AMD after the U.S. and EU regulators agreed for a Phase 2 trial for the candidate targeted at the indication. “We view it as a materially derisking event for wAMD and other future ocular indications based on the AAV.7m8 chassis,” the analysts wrote referring to the vector capsid used in the gene therapy candidate. The analysts expect a series of data readouts in 2023 and point out that Adverum (ADVM) has extended its cash runway by one year to 2025 following the restructuring. The price target raised to $4 from $3 is in line with the current average price target for the stock on Wall Street.

Analyseartikel • May 12

We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analyseartikel • Jul 17

We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analyseartikel • Apr 06

We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analyseartikel • Feb 13

Don't Ignore The Fact That This Insider Just Sold Some Shares In Adverum Biotechnologies, Inc. (NASDAQ:ADVM)

We'd be surprised if Adverum Biotechnologies, Inc. ( NASDAQ:ADVM ) shareholders haven't noticed that the President...

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:ADVM - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2027	N/A	-203	-238	N/A	3
12/31/2026	0	-194	-215	-211	6
12/31/2025	0	-195	-187	-171	6
9/30/2025	N/A	-185	-138	-138	N/A
6/30/2025	1	-169	-132	-131	N/A
3/31/2025	1	-151	-113	-112	N/A
12/31/2024	1	-131	-93	-92	N/A
9/30/2024	1	-119	-86	-86	N/A
6/30/2024	N/A	-119	-89	-88	N/A
3/31/2024	N/A	-120	-93	-92	N/A
12/31/2023	4	-122	-92	-91	N/A
9/30/2023	4	-126	-89	-88	N/A
6/30/2023	4	-133	-97	-96	N/A
3/31/2023	4	-146	-109	-102	N/A
12/31/2022	N/A	-155	-120	-108	N/A
9/30/2022	N/A	-156	-131	-115	N/A
6/30/2022	N/A	-154	-130	-109	N/A
3/31/2022	N/A	-155	-133	-114	N/A
12/31/2021	8	-146	-123	-108	N/A
9/30/2021	8	-149	-116	-104	N/A
6/30/2021	8	-138	-115	-105	N/A
3/31/2021	8	-123	-97	-88	N/A
12/31/2020	N/A	-118	-91	-79	N/A
9/30/2020	N/A	-99	-91	-72	N/A
6/30/2020	0	-87	-77	-55	N/A
3/31/2020	0	-73	-71	-50	N/A
12/31/2019	0	-64	-68	-49	N/A
9/30/2019	0	-61	-58	-47	N/A
6/30/2019	1	-66	N/A	-54	N/A
3/31/2019	1	-70	N/A	-54	N/A
12/31/2018	2	-73	N/A	-54	N/A
9/30/2018	2	-72	N/A	-53	N/A
6/30/2018	2	-65	N/A	-47	N/A
3/31/2018	2	-57	N/A	-47	N/A
12/31/2017	2	-56	N/A	-45	N/A
9/30/2017	2	-64	N/A	-42	N/A
6/30/2017	2	-64	N/A	-41	N/A
3/31/2017	2	-114	N/A	-38	N/A
12/31/2016	1	-114	N/A	-38	N/A
9/30/2016	2	-105	N/A	-39	N/A
6/30/2016	2	-105	N/A	-39	N/A
3/31/2016	2	-53	N/A	-40	N/A
12/31/2015	2	-47	N/A	-35	N/A
9/30/2015	2	-44	N/A	-31	N/A
6/30/2015	1	-38	N/A	-27	N/A
3/31/2015	1	-36	N/A	-12	N/A
12/31/2014	1	-29	N/A	-6	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ADVM wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ADVM wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ADVM wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ADVMDie Einnahmen des Unternehmens (87.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (12.5% pro Jahr).

Hohe Wachstumseinnahmen: ADVMDie Einnahmen des Unternehmens (87.4% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ADVM in 3 Jahren voraussichtlich hoch sein wird

Wachstumsunternehmen entdecken

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2025/12/10 23:25
Aktienkurs zum Tagesende	2025/12/08 00:00
Gewinne	2025/09/30
Jährliche Einnahmen	2024/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Adverum Biotechnologies, Inc. wird von 12 Analysten beobachtet. 6 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
Graig Suvannavejh	Goldman Sachs
Biren Amin	Jefferies LLC
Mani Foroohar	Leerink Partners LLC

This company has been acquired

Adverum Biotechnologies Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates fall by 99%

Price target decreased by 44% to US$11.00

Consensus EPS estimates fall by 11%

Price target decreased by 24% to US$19.75

Price target decreased to US$3.67

Price target decreased to US$3.67

Recent updates

Adverum Biotechnologies, Inc.(NasdaqCM:ADVM) dropped from Russell Microcap Growth Index

Consensus revenue estimates fall by 99%

New major risk - Financial position

Price target decreased by 44% to US$11.00

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire Adverum Biotechnologies, Inc. (NasdaqCM:ADVM) for $80.2 million.

Consensus EPS estimates fall by 11%

Adverum Biotechnologies, Inc. Announces Completion of Screening for Pivotal Phase 3 ARTEMIS Trial of Ixo-Cov for Wet Age-Related Macular Degeneration

Adverum Biotechnologies, Inc. announced that it has received $10 million in funding from Frazier Life Sciences Management, LP

Price target decreased by 24% to US$19.75

Adverum Biotechnologies, Inc.(NasdaqCM:ADVM) dropped from Russell 3000 Value Index

Adverum Biotechnologies, Inc., Annual General Meeting, Jun 17, 2025

Adverum Biotechnologies, Inc. Auditor Raises 'Going Concern' Doubt

Adverum Biotechnologies, Inc. announced delayed annual 10-K filing

Adverum Biotechnologies, Inc. Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD

Adverum Biotechnologies Announces Positive 52-Week Luna and 4-Year Optic Results, and Provides Key Pivotal Program Design Elements

Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients

Adverum Biotechnologies, Inc. Appoints Jason L. Mitchell as Chief Commercial Officer

Adverum Biotechnologies Announces Fda Regenerative Medicine Advanced Therapy (Rmat) Designation Granted for Ixo-Vec for the Treatment of Wet Amd

Adverum Biotechnologies, Inc. Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting

Adverum Biotechnologies, Inc. Announces Executive Changes

Adverum Biotechnologies, Inc., Annual General Meeting, Jun 17, 2024

Adverum Biotechnologies, Inc. announced that it has received $127.5 million in funding from a group of investors

Adverum Biotechnologies, Inc. Announces Positive Preliminary Efficacy and Safety Data from Luna Phase 2 Trial of Ixo-Cov in Patients with Wet AMD

Adverum Biotechnologies, Inc. Announces Stipulation and Agreement of Settlement

Adverum Biotechnologies, Inc. announced that it expects to receive $127.5 million in funding from a group of investors

Adverum Biotechnologies, Inc. Appoints Romuald Corbau as Chief Scientific Officer and Member of Executive Committee

Adverum Biotechnologies Receives a Letter from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

Adverum Biotechnologies, Inc. Appoints C. David Nicholson to the Board of Directors

Adverum Biotechnologies, Inc. Announces Positive Aflibercept Protein Level Data from the Luna Phase 2 Trial

Adverum Biotechnologies, Inc. Appoints R. Andrew Andy Ramelmeier as Chief Technology Officer

Adverum Biotechnologies, Inc. Completes Enrollment of Phase 2 LUNA Trial in Wet AMD

Adverum Biotechnologies Receives Nasdaq Notice on Regained Compliance with Minimum Bid Price Requirement

Adverum Biotechnologies, Inc. Announces Resignation of Richard Beckman as Chief Medical Officer

Adverum Biotechnologies, Inc. Receives Approval from the Listing Qualifications Department of Nasdaq to Transfer the Listing of Common Stock from Nasdaq Global Market to Nasdaq Capital Market

Adverum Biotechnologies, Inc. Presents Nonclinical Data in Support of Ixo-vec’s Phase 2 Clinical Development at ASGCT 2023 Annual Meeting

We're Keeping An Eye On Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Price target decreased to US$3.67

Price target decreased to US$3.67

We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully

Adverum Biotechnologies GAAP EPS of -$0.44 misses by $0.10

Price target increased to US$4.33

Adverum gains 13% to reach three-month high after Truist upgrade

We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully

Price target increased to US$4.33

High number of new directors

Independent Director recently sold US$109k worth of stock

Price target increased to US$4.33

Chief Business Officer & Acting CFO Christopher DeRespino has left the company

Price target decreased to US$3.57

Consensus revenue estimates increase to US$6.00m

Consensus forecasts updated

We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Price target decreased to US$17.11

We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Independent Chairman recently bought US$99k worth of stock

New 90-day low: US$10.55

Analysts lower revenue estimates to US$230.0k

Don't Ignore The Fact That This Insider Just Sold Some Shares In Adverum Biotechnologies, Inc. (NASDAQ:ADVM)

New 90-day high: US$14.36

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken

Unternehmensanalyse und Finanzdaten Status

Datenquellen

Analysemodell und Schneeflocke

Metriken für Industrie und Sektor